A
ALLO
Allogene Therapeutics, Inc. Common Stock
$1.30
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of Allogene Therapeutics, Inc. Common Stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$0.49
P/E
—
Data as of Oct 8
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: -$0.15
Oct 29
Posts
No posts about ALLO yet.
About Allogene Therapeutics, Inc. Common Stock
Allogene Therapeutics is a US biotech company developing cancer treatments called CAR T therapies. These therapies use immune cells from healthy donors, engineered to attack cancer, and ready to use off the shelf instead of being made from each patient's own cells. Allogene has almost no sales. It pays its bills by raising money from investors and from small collaboration revenue, and it hopes to earn real income if a drug wins approval.